ARTICLE | Company News
Strongbridge hands off Macrilen to Novo for sizable return
November 2, 2018 7:51 PM UTC
Less than a year after acquiring U.S. and Canadian rights to Macrilen macimorelin acetate, Strongbridge Biopharma plc (NASDAQ:SBBP) handed those rights off to Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO), netting a 6x return.
FDA approved the oral ghrelin-mimetic growth hormone secretagogue in December 2017, making it the only oral drug approved in the U.S. to diagnose adult growth hormone deficiency. Macrilen has Orphan Drug status in the U.S...
BCIQ Target Profiles